--- title: "ROIS establishes itself as Global CDMO with US Expansion" type: "News" locale: "en" url: "https://longbridge.com/en/news/285062210.md" description: "ROIS CDMO has acquired a commercial injectable manufacturing facility in Phoenix, Arizona, marking a significant step in its evolution as a global Contract Development and Manufacturing Organisation (CDMO). This expansion enhances ROIS's capabilities in developing and manufacturing injectable medicines, particularly for rare diseases, obesity, and cancer. The company aims to better support its global customers and reinforce its commitment to innovation and quality in injectable drug development. ROIS is recognized for its high-capacity manufacturing and has received approvals from major regulatory bodies." datetime: "2026-05-04T11:00:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285062210.md) - [en](https://longbridge.com/en/news/285062210.md) - [zh-HK](https://longbridge.com/zh-HK/news/285062210.md) --- # ROIS establishes itself as Global CDMO with US Expansion **_ROIS CDMO closes the acquisition of US injectable manufacturing facility to strengthen global capacity_** , /PRNewswire/ -- **_ROIS, a Global CDMO with its routes in Spain_**, announced on April 1st, the acquisition of a commercial injectable manufacturing and packaging facility in **Phoenix, Arizona (USA)**. The move marks a key step in ROIS's evolution into a global Contract Development and Manufacturing Organisation (CDMO), adding US-based sterile fill-finish capability while building on its strong European base. In addition to attending the internal launch on April 9, local Mayor Kate Gallego supported the announcement in her April State of the City address: "ROIS makes specialized injectables that can treat rare diseases, obesity and cancer." She added, "This is a promising area of growth in medical care and I'm excited that between our great university partners and ROIS, Phoenix is ahead of the curve." The Phoenix site strengthens ROIS's ability to develop and manufacture injectable medicines at commercial scale, enhancing capacity, flexibility and speed as well as adding new capabilities for ADC's and Cytotoxic LYO fill-finish. "This is a pivotal moment for us," said Kimberlee Steele, newly appointed Chief Commercial Officer. "Our US expansion positions ROIS to better support customers worldwide." ROIS has built its reputation as a trusted partner in injectable drug development and manufacturing, with end-to-end capabilities spanning clinical production through to large-scale commercial supply. The company continues to invest in **facilities, equipment, and talent** to meet growing demand and ensure long-term capacity for its partners worldwide. With an expanded global footprint, ROIS is reinforcing its commitment to innovation, quality, and growth — positioning itself as the partner of choice for injectable medicines. For more information, visit **www.roiscdmo.com**. **_About ROIS_** ROIS has one of the top three sterile CDMO capacities for injectables worldwide, ROIS is trusted by over 30 global pharma clients to deliver compliant, high-capacity manufacturing with precision and speed. With approvals from leading regulators — including the FDA, EMA, PMDA, KFDA, ANVISA, and MHRA — ROIS offers end-to-end support across multiple formats including syringes, cartridges, and vials. Photo: https://mma.prnewswire.com/media/2969215/ROIS\_Team.jpg Photo: https://mma.prnewswire.com/media/2969214/ROIS\_Phoenix.jpg Logo: https://mma.prnewswire.com/media/2970481/ROIS\_Logo.jpg View original content to download multimedia:https://www.prnewswire.com/news-releases/rois-establishes-itself-as-global-cdmo-with-us-expansion-302759256.html SOURCE ROIS ### Related Stocks - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [BIS.US](https://longbridge.com/en/quote/BIS.US.md) ## Related News & Research - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md) - [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md) - [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md) - [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md) - [Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference](https://longbridge.com/en/news/286652404.md)